公开(公告)号：US12209255B2

公开(公告)日：2025-01-28

申请号：US16745944

申请日：2020-01-17

Applicant: Astellas Institute for Regenerative Medicine

Inventor： Robert P. Lanza ,  Erin Kimbrel

IPC: C12N5/0775 ,  A61K35/28 ,  A61K35/51 ,  C12N5/071 ,  C12N5/0789 ,  C12N13/00 ,  C12N15/01

Abstract: The present invention relates to methods of generating and expanding hitman embryonic stem cell derived mesenchymal-like stem/stromal cells. These hES-MSCs are characterized at least in part by the low level of expression of IL-6. These cells are useful for the prevention and treatment of T cell related autoimmune disease, especially multiple sclerosis, as well as for delivering agents across the blood-brain barrier and the blood-spinal cord barrier. Also provided is a method of selecting clinical grade hES-MSC and a method of modifying MSC to produced a MSC with specific biomarker profile. The modified MSC are useful for treatment of various diseases.

公开(公告)号：US20250025510A1

公开(公告)日：2025-01-23

申请号：US18714813

申请日：2022-12-01

Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

Inventor： Khalid SHAH ,  Filippo ROSSIGNOLI

IPC: A61K35/28 ,  A61K35/17 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0775

Abstract: This technology describes novel cell based combined therapeutic modalities that include a stem cell engineered to secrete a multispecific T cell engager (MiTE) polypeptide construct and an isolated population of T cells that are autologous to the subject.

公开(公告)号：US12202880B2

公开(公告)日：2025-01-21

申请号：US17741438

申请日：2022-05-10

Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO

Inventor： Brian Freed ,  Christina Roark ,  Elizabeth Sunderhaus

IPC: C07K14/74 ,  A61K35/17 ,  A61K35/28 ,  A61K39/00 ,  A61P37/02 ,  A61P37/06 ,  C12N5/0775 ,  C12N15/62 ,  C12N15/86 ,  C12Q1/6881 ,  A61K38/00

Abstract: Methods of preventing or treating autoimmune disease are disclosed. In some cases, subjects with having or at risk of developing autoimmune disease are identified as possessing one or more autoimmunity-susceptibility HLA alleles at one or more HLA loci. In many cases, the HLA loci are selected from Class I and Class II loci, for example Class I A, B, and C, and Class II DQ, DR, and DP. In many cases, subjects suffering from or at risk of developing an autoimmune disease may be administered a plurality engineered autologous HSCs modified to carry and express a variant susceptibility allele having at least one mutation in the antigen binding cleft that alters antigen binding and/or specificity of that variant HLA molecule. In many embodiments, the engineered HSCs are CD34+ immune cells that express one or more modified HLA proteins.

公开(公告)号：US20250019660A1

公开(公告)日：2025-01-16

申请号：US18745400

申请日：2024-06-17

Applicant: The Regents of the University of California

Inventor： Richard KLEMKE ,  Huawei WANG

IPC: C12N5/0775 ,  A61K9/00 ,  A61K35/12 ,  A61K35/17 ,  A61K35/28 ,  A61K38/20 ,  A61K39/00 ,  A61K39/215 ,  A61P35/00 ,  C12N5/0783 ,  C12N5/10 ,  C12N15/85 ,  C12N15/88

Abstract: Provided are cytoplasts (enucleated cells), methods for making cytoplasts, compositions comprising cytoplasts, and methods for using cytoplasts.

公开(公告)号：US12194062B2

公开(公告)日：2025-01-14

申请号：US16191816

申请日：2018-11-15

Applicant: WEIRD SCIENCE LLC

Inventor： Serhat Gumrukcu

IPC: A61K35/28 ,  A61K31/664 ,  A61K31/675 ,  A61K35/12 ,  A61K39/00 ,  A61K45/06 ,  A61P31/18 ,  C07K14/435 ,  C12N9/02 ,  C12N15/113 ,  C12N15/86

Abstract: The disclosure relates generally to methods and compositions for performing bone marrow transplants using a non-myeloablative chemotherapeutic agent and chemotherapeutic-resistant cells. Using the methods and compositions described herein, a patient's bone marrow may be reconstituted and the patient avoids adverse side effects, including myeloablation and/or an impaired immune system.

公开(公告)号：US20240425815A1

公开(公告)日：2024-12-26

申请号：US18691971

申请日：2022-09-21

Applicant: AARHUS UNIVERSITET

Inventor： Hermanus Johannes Marco EIJKEN ,  Toke ALSTRUP

IPC: C12N5/0775 ,  A01N1/02 ,  A61K35/28 ,  C12N13/00

Abstract: The present invention relates to inactivated stem cells, which can be stored for several days in a refrigerator (above 0° C.), preferably in the range 0.1-10° C.) and still maintain their cellular and phenotypic integrity as well as therapeutic potential. In particular, the present invention relates to medical uses of such refrigerator-stored inactivated stem cell solution.

公开(公告)号：US20240417691A1

公开(公告)日：2024-12-19

申请号：US18701379

申请日：2022-10-14

Applicant: NISSAN CHEMICAL CORPORATION

Inventor： Masashi IWAKAMI ,  Daisuke HATANAKA ,  Katsuhiko KIDA

IPC: C12N5/0775 ,  A61K35/28 ,  A61P29/00 ,  C12N5/00

Abstract: The present invention provides a method for culturing an adherent cell, including a step of suspension culturing the adherent cell in a medium containing a nanofiber composed of a water-insoluble polysaccharide, wherein the culture is performed along with stirring.

公开(公告)号：US20240409898A1

公开(公告)日：2024-12-12

申请号：US18810282

申请日：2024-08-20

Applicant: Mesoblast International Särl

Inventor： Paul Simmons ,  Colby Suire ,  Fiona See

IPC: C12N5/0775 ,  A61K35/28 ,  A61K47/36 ,  G01N33/68

Abstract: The present invention relates to a method for determining the biological activity or therapeutic efficacy of cultured mesenchymal lineage precursor cells or stem cells the based on their released TGF-ϑ levels in culture. The present invention also relates to isolated populations of mesenchymal lineage precursor cells or stem cells selected based on the level of TGF-ϑ levels released by such cells in culture. The present invention further relates to treatment of a subject suffering from a degenerative disc disease by administering such selected cell populations.

公开(公告)号：US20240408142A1

公开(公告)日：2024-12-12

申请号：US18206091

申请日：2023-06-06

Applicant: Qingdao Jinmotang Biotechnology Co., LTD.

Inventor： Feng SHAO ,  Shuai GAO ,  Juan WANG ,  Chunyu SHAO

IPC: A61K35/28

Abstract: A preparation method for canine whole blood hematopoietic stem cells includes the following steps: step 1: performing matching of specific pathogen free (SPF) dogs, where the blood type of the SPF dogs is negative blood, the SPF dogs need to be immunized with a conventional pentavaccine, an indirect enzyme-linked immunosorbent assay (ELISA) method is used for testing, the antibody titer thereof reaches over 29, and the SPF dogs need to be matched with diseased dogs; and step 2: performing physical examination of the dogs, where venous blood is regularly collected for hematology and serum biochemical testing before blood sampling of the matched dogs. According to the present disclosure, the experimental dogs, namely the SPF dogs are free of special pathogens, and have great advantages in the aspect of safety performance, such that the prepared blood has good safety performance.

公开(公告)号：US12162918B2

公开(公告)日：2024-12-10

申请号：US17260681

申请日：2019-07-18

Applicant: Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus

Inventor： Daniela S. Krause ,  Divij Verma

IPC: C07K14/51 ,  A61K35/28 ,  A61K38/00 ,  C12N5/0789

Abstract: The present invention pertains to periostin compounds for use in the prevention and treatment of haematological complications, such as adverse events from therapy or haematological diseases. In context of the present invention a therapeutic was developed for enhancing haematopoiesis in patients and to support haematopoietic stem cell (HSC) transplantation (HSCT) by administration of periostin compounds to patients or stem cell donors, or by contacting HSC directly with periostin compounds, for example ex vivo, to improve a transplant HSC preparation. The present invention provides periostin derived compounds such as polypeptides, peptides, nucleic acids, and other periostin-derived agents, that are used both in therapeutic applications and for improving haematopoiesis, for example in stem cell donor subjects or to treat HSC in vitro.